Financial Performance - Q1 2025 revenue increased by 6.2% year-over-year, from $26 million to $27.6 million[19] - Net income turned around from a loss of $0.24 million in Q1 2024 to a profit of $1.95 million in Q1 2025[19] - Free cash flow increased by 63.6% from $2.2 million in Q1 2024 to $3.6 million in Q1 2025[21] - Adjusted EBITDA increased by 63.6% from $3.6 million in Q1 2024 to $5.6 million in Q1 2025[41] - Adjusted net income increased by 941% from $0.2 million in Q1 2024 to $2.3 million in Q1 2025[41] Strategic Initiatives - The company is focusing on AI-driven solutions to transform healthcare[1,26] - The company launched an AI Center of Excellence in Bagh, targeting 500 AI professionals by year-end[28,29] - The company is expanding its specialty EHR portfolio with a focus on GI and Dermatology[35,36] - The company completed acquisitions of MesaBilling LLC and RevNu Medical Management in early 2025 to enhance client base and expand reach into underserved specialty markets[24] Capital Structure - Post-conversion capital structure shows common equity at 62% and preferred equity at 38%[21] - Pre-conversion capital structure shows common equity at 31% and preferred equity at 69%[21]

Exhibit 99.1 CareCloud Delivers Growth and Strong Cash Flow in Q1 2025, Advances AI and Acquisition Strategy SOMERSET, N.J. May 6, 2025 (GLOBE NEWSWIRE) - CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the three months ended March 31, 2025. CareCloud's strategic execution, AI-driven innovation, and disciplined financial management have fueled a transformational turnaround, positioning the Company for sustaine ...

Core Insights - CareCloud, Inc. reported strong financial results for Q1 2025, highlighting a transformational turnaround driven by strategic execution, AI innovation, and disciplined financial management [1][3] - The company is positioned for sustained profitability and long-term growth, with management set to discuss growth strategies in a conference call [1][9] Financial Highlights - Revenue for Q1 2025 was $27.6 million, a 6% increase from $26.0 million in Q1 2024 [6] - GAAP net income reached $1.9 million, compared to a net loss of $241,000 in Q1 2024 [6] - Adjusted EBITDA was $5.6 million, reflecting a 52% increase from $3.7 million in Q1 2024 [6] - Adjusted net income was $2.3 million, equating to $0.05 per share [6] Strategic Developments - CareCloud launched its AI Center of Excellence, aiming to build a team of 500 AI specialists by Q4 2025 [6] - The company completed the conversion of 3.5 million Series A preferred shares into 26 million common shares, reducing annual dividend commitments by approximately $7.7 million [6] - Preferred stock dividends resumed in February 2025, with six months of dividends declared to date [6][4] 2025 Guidance - CareCloud anticipates full-year 2025 revenue between $111 million and $114 million, based on expectations of organic growth and client additions [7][8] - Adjusted EBITDA is projected to be between $26 million and $28 million for the full year [8] - Earnings per share (EPS) is expected to range from $0.10 to $0.13 [8]

Core Insights - CareCloud, Inc. has launched its AI Center of Excellence (AI CoE), aimed at delivering scalable, domain-specific AI solutions for healthcare [1][2] - The AI CoE began operations with a team of over 50 professionals and plans to expand to 500 by Q4 2025, positioning itself as the largest dedicated healthcare AI initiative globally [2][3] - The initiative is fully self-funded, showcasing CareCloud's strong cash flows and efficient cost structure, which allows for accelerated innovation and cost-effective solutions [2][4] Company Strategy - The AI CoE is a pivotal part of CareCloud's growth strategy, emphasizing the need for innovation in the healthcare sector to remain competitive [3][5] - CareCloud aims to integrate AI across its technology stack, enhancing operational efficiency and clinical outcomes while reducing administrative burdens [4][5] - The company is focused on developing proprietary healthcare AI models, streamlining clinical workflows, and improving patient engagement through AI-driven personalization [7] Industry Impact - The healthcare industry is rapidly adopting AI, and CareCloud's AI CoE is positioned to lead this transformation by driving operational changes and improving care delivery [5][6] - By leveraging 25 years of clinical and financial data, CareCloud is developing AI solutions that are compliant with HIPAA regulations, ensuring immediate real-world impact [2][4] - The focus on predictive analytics will enable earlier identification of reimbursement risks and operational bottlenecks, further enhancing the efficiency of healthcare providers [7]

Core Insights - CareCloud, Inc. will release its financial results for Q1 2025 on May 6, 2025, before market opens [1] - A conference call for investors will follow at 8:30 a.m. Eastern Time on the same day [1] Company Overview - CareCloud is a leader in healthcare technology and generative AI solutions, serving medical practices and health systems across the nation [1] - The company offers a suite of solutions aimed at improving financial and operational performance, streamlining clinical workflows, and enhancing patient experience [4] - More than 40,000 providers rely on CareCloud for improving patient care while reducing administrative burdens and operating costs [4]

SOMERSET, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the "Company") (NASDAQ:CCLD, CCLDO)), a leading provider of practice management, healthcare technology and AI-driven solutions to medical practices across the country, is pleased to announce its participation in the 15th Annual LD Micro Invitational at the Westin Grand Central Hotel in New York on April 9-10, 2025. The Company is scheduled to present on April 10, 2025 at 3:30 p.m. ET. CareCloud's management team will deliver a corporate pre ...

Core Insights - CareCloud, Inc. has announced the acquisition of RevNu Medical Management, an audiology-focused revenue cycle management company, marking a strategic expansion into a specialty care market [1][2] - The U.S. audiology market includes approximately 24,000 employed audiologists and hearing aid specialists, with annual spending on hearing aids exceeding $5 billion, indicating significant growth potential in this sector [2] - The acquisition is expected to be accretive within ninety days and will enhance CareCloud's capabilities in the hearing healthcare space through the deployment of AI-powered revenue cycle management [3] Company Overview - CareCloud provides practice management, healthcare technology, and AI-driven solutions to medical practices, helping over 40,000 providers improve patient care while reducing administrative burdens [4] - The company aims to leverage its advanced technology infrastructure and culture of innovation to enhance client outcomes and unlock new growth potential in the audiology market [3][4] Market Context - The audiology segment remains minimally penetrated by outsourced revenue cycle management and practice management vendors, presenting an opportunity for CareCloud and RevNu to capture new market share [2] - RevNu is recognized as one of the leading RCM providers in the audiology space, and its integration with CareCloud is expected to accelerate growth in underserved markets [2][3]

Core Insights - CareCloud, Inc. has expanded its services with Alpine Ear, Nose & Throat PC, implementing the FrontDesk Assist solution to enhance operational efficiency and patient satisfaction [1][4] - The partnership aims to streamline front-office operations, resulting in shorter patient wait times and improved appointment scheduling [2][3] Company Overview - CareCloud is a provider of healthcare technology and AI-powered revenue cycle management solutions, serving over 40,000 providers [6] - The company focuses on increasing financial and operational performance while reducing administrative burdens for healthcare organizations [6] Product Details - FrontDesk Assist is designed to support critical front-office functions such as appointment scheduling, referral management, surgery estimates, and prior authorizations [2][4] - The solution is now available nationwide to healthcare practices across various specialties, complementing CareCloud's existing EHR and RCM platforms [4]

Core Viewpoint - CareCloud, Inc. has declared monthly cash dividends for its Series A and Series B Preferred Stocks for March and April 2025, reflecting the company's commitment to returning value to shareholders [1][2]. Dividend Details - The monthly dividend for Series A Preferred Stock is $0.18229 per share for both March and April 2025, with an additional payment of $0.04688 per share [2]. - The monthly dividend for Series B Preferred Stock is also $0.18229 per share for both March and April 2025 [2][3]. - The ex-dividend and record dates for both series are March 31, 2025, and April 30, 2025, respectively, with payment dates set for April 15, 2025, and May 15, 2025 [2][4]. Preferred Stock Information - Series A Preferred Stock has a cumulative cash dividend rate of 8.75% per annum based on a $25.00 liquidation preference, equating to $2.1875 per annum per share [2][3]. - Series B Preferred Stock also has a cumulative cash dividend rate of 8.75% per annum based on a $25.00 liquidation preference, equating to $2.1875 per annum per share [3]. - The Series A Preferred Stock was converted into common stock on March 6, 2025, leading to its voluntary delisting from the Nasdaq Global Market [5]. Redemption Options - The company has the option to redeem Series A Preferred Stock at a price of $25.00 per share, plus any accumulated and unpaid dividends, with a notice period of 30 to 60 days [5]. - For Series B Preferred Stock, the redemption prices vary based on the date, starting at $25.50 per share for redemptions on or after February 15, 2025 [6].

Financial Performance - The company reported net revenue of $110.837 million for the year ended December 31, 2024, a decrease of 5.2% from $117.059 million in 2023[261] - Adjusted EBITDA for 2024 was $24.057 million, significantly up from $15.429 million in 2023, representing a year-over-year increase of 55.5%[261] - The company achieved a GAAP net income of $7.851 million in 2024, compared to a net loss of $48.674 million in 2023[261] - Adjusted operating income for 2024 was $11.455 million, up from $5.967 million in 2023, resulting in an adjusted operating margin of 10.3% compared to 5.1% in the previous year[264] - Non-GAAP adjusted net income for 2024 was $10.520 million, compared to $4.801 million in 2023, indicating a substantial improvement in profitability[264] - The company reported a non-GAAP adjusted earnings per share of $0.65 for 2024, an increase from $0.30 in 2023[266] - The company’s GAAP operating margin improved to 8.2% in 2024 from a negative 40.2% in 2023[264] - Operating income for 2024 was $9,121,000, compared to an operating loss of $47,115,000 in 2023[267] - Net income for 2024 was $7,851,000, a significant improvement from a net loss of $48,674,000 in 2023[267] - Net income attributable to common shareholders was a loss of $4,459,000 in 2024, an improvement from a loss of $64,348,000 in 2023[267] Expenses and Cost Management - The company’s offshore operations accounted for approximately 15% of total expenses in 2024, up from 9% in 2023, with personnel-related costs making up about 75% of these expenses[256] - Total operating expenses decreased to $101,716,000 in 2024 from $164,174,000 in 2023, reflecting a reduction of 38%[267] - Direct operating costs represented about 13% of total costs in 2024, compared to 11% in 2023, indicating a slight increase in operational efficiency[282] - General and administrative expenses accounted for approximately 22% of total expenses in 2024, up from 17% in 2023, suggesting increased administrative costs[284] - Selling and marketing expenses decreased by $3.4 million or 35% to $6.2 million in 2024 from $9.7 million in 2023[314] - General and administrative expenses decreased by $5.3 million or 25% to $16.1 million in 2024 from $21.5 million in 2023[315] - Research and development expenses decreased by $955,000 or 20% to $3.8 million in 2024 from $4.7 million in 2023[316] - Total operating expenses for 2024 were $101.7 million, a decrease of $62.5 million or 38% from $164.2 million in 2023[313] Cash Flow and Financial Position - Cash balance increased to $5,145,000 in 2024 from $3,331,000 in 2023[268] - Positive cash flow from operations increased to $20.6 million in 2024 from $15.5 million in 2023, representing a 34% increase[331] - Cash used in investing activities decreased to $7.4 million in 2024 from $11.6 million in 2023, a reduction of $4.2 million[336] - Cash used in financing activities was $11.3 million in 2024, down from $13.3 million in 2023, including the full repayment of a $10 million credit line[337] - The company recorded a net increase in cash of $1.8 million in 2024, compared to a decrease of $8.9 million in 2023, marking a turnaround of $10.8 million[331] Client and Revenue Metrics - The company served approximately 40,000 providers across about 2,600 practices as of December 31, 2024, maintaining a stable client base[275] - Customer renewal rates improved to 95% in 2024 from 91% in 2023, reflecting strong client retention[276] - Revenue from technology-enabled business solutions accounted for approximately 67% of total revenues in 2024, up from 65% in 2023[277] - Revenue from technology-enabled business solutions was $73.7 million in 2024, down from $76.6 million in 2023[310] - Professional services revenue decreased by $4.8 million in 2024 compared to 2023, primarily due to the winding down of services for two large accounts[311] Goodwill and Impairment - Goodwill impairment charges in 2023 amounted to $42,000,000, reflecting a significant write-down related to the Healthcare IT reporting unit[287] - Goodwill impairment of approximately $2 million was recorded in October 2023, with an additional impairment of approximately $40 million recorded in December 2023[305] - Goodwill impairment charge of $42 million was recorded in 2023, resulting in the reversal of the entire deferred tax liability at December 31, 2023[325] Shareholder Information - The total fully diluted shares increased to 16,498,736 in 2024 from 16,614,000 in 2023[266] - The weighted average common shares outstanding increased to 16,146,975 in 2024 from 15,669,472 in 2023[267] - Shareholders' equity increased to $49,774,000 in 2024 from $41,717,000 in 2023[268] Tax and Interest - The income tax provision for 2024 was $160,000, contrasting with a tax benefit of $364,000 in 2023[323] - Interest income decreased by $66,000 or 43% to $88,000 for the year ended December 31, 2024, compared to $154,000 in 2023[320] - Interest expense decreased by $294,000 or 25% to $900,000 for the year ended December 31, 2024, from $1.2 million in 2023[321] - Other expense - net improved to $298,000 in 2024 from $883,000 in 2023, primarily due to a foreign exchange gain of $130,000 compared to a loss of $790,000 in 2023[322] Future Outlook - The company plans to continue leveraging its offshore operations to maintain competitive cost advantages in the healthcare IT sector[256] - The company expects to achieve further economies of scale as it grows, potentially reducing direct operating costs as a percentage of revenue[282] - The company has a total federal NOL carry forward of approximately $265 million, with $187 million expiring between 2031 and 2038[328]